Triple antiviral therapy in HCV positive patients who failed prior combination therapy

Silvia Fargion, Mauro Borzio, Alessandra Maraschi, Antonietta Cargnel, Giovanni Bolognini, Gian Piero Benetti, Anna Ludovica Fracanzani, Giovanni Pinzello, Maria Vinci, Guido Croce, Andrea Capretti, Riccardo Giorni, Massimo Pozzi, Alessandro Redaelli, Alberto Prada, Barbara Omazzi, Aldo Autolitano, Paolo Del Poggio

Research output: Contribution to journalArticle

Abstract

Aim: To assess the efficacy of triple therapy (peginterferon or high dose standard interferon, plus ribavirin and amantadine) in nonresponders to prior combination therapy. Methods: A total of 196 patients were enrolled in a multicenter, open, randomized study. Patients were given 180 μg/wk of peginterferon-alpha-2a (40 kD) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group A) or interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group B). Results: Overall sustained virologic response (SVR) was 26.6% (32.1% and 19.5% in group A and B, P = 0.057). Baseline ALT >120 UI/L (OR 2.4; 95% CI:1.11 to 5.20; P = 0.026) and HCV RNA negativity after 12 wk (OR 8.7; 95% CI: 3.87 to 19.74; P <0.0001) were independently associated with SVR. Therapy discontinuation occurred less frequently in patients treated with peginterferon than standard interferon (P = 0.036). Conclusion: More than 25% of nonresponders to combination therapy can eradicate HCV infection when retreated with triple therapy, especially if they have a high baseline ALT and are treated with pegylated interferon.

Original languageEnglish
Pages (from-to)5293-5300
Number of pages8
JournalWorld Journal of Gastroenterology
Volume12
Issue number33
Publication statusPublished - Sep 7 2006

    Fingerprint

Keywords

  • Amantadine
  • Hepatitis C
  • Nonresponders
  • Peginterferon
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fargion, S., Borzio, M., Maraschi, A., Cargnel, A., Bolognini, G., Benetti, G. P., Fracanzani, A. L., Pinzello, G., Vinci, M., Croce, G., Capretti, A., Giorni, R., Pozzi, M., Redaelli, A., Prada, A., Omazzi, B., Autolitano, A., & Del Poggio, P. (2006). Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World Journal of Gastroenterology, 12(33), 5293-5300.